Summary
Palvella Therapeutics (PVLA) has shown significant price appreciation, gaining 90% since a Trend Seeker buy signal on 2/5, and 105.81% over the last year.
The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials.
Technical indicators are strong with 88% buy signals, a high RSI of 85.00%, and the stock trading above key moving averages.
Despite positive analyst sentiment and strong technicals, the stock is volatile and speculative; diversification and disciplined stop-loss strategies are recommended
The Chart of the Day belongs to the biotechnology company Palvella Therapeutics (PVLA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 2/5 the stock gained 90%.
PVLA Price vs Daily Moving Averages:
PVLA (Barchart)
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart Technical Indicators:
- 88% technical buy signals
- 25.18+ Weighted Alpha
- 105.81% gain in the last year
- Trend Seeker buy signal
- Above its 20, 50 and 100 day moving averages
- 12 new highs and up 73.31% in the last month
- Relative Strength Index 85.00%
- Technical support level at $25.67
- Recently traded at $27.99 with 50 day moving average of $16.30
Fundamental Factors:
- Market Cap $282 million
- Analysts have not given firm Revenue and Earnings estimates
Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:
- Wall Street analysts issued 4 strong buy opinions on the stock
- CFRAs MarketScope rates the stock a hold
- MorningStar thinks the stock is 12% over valued
- Only 72 investors monitor the stock on Seeking Alpha
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/Facebook%20headquarters%20sign%20by%20Greg%20Bulla%20via%20Unsplash.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20phone%20and%20stock%20data-by%20Poetra_RH%20via%20Shutterstock.jpg)
